Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 11
2006 3
2007 4
2008 7
2009 3
2010 8
2011 8
2012 3
2013 2
2014 6
2015 10
2016 4
2017 6
2018 3
2019 1
2020 8
2021 1
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Pulmonary tuberculosis.
Brunner M, Thurnher D. Brunner M, et al. Among authors: thurnher d. Wien Klin Wochenschr. 2007;119(13-14):404. doi: 10.1007/s00508-007-0826-z. Wien Klin Wochenschr. 2007. PMID: 17671820 No abstract available.
Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group position paper based on the EORTC 1420 'Best of' and 24954 'larynx preservation' study.
Simon C, Caballero C, Gregoire V, Thurnher D, Koivunen P, Ceruse P, Spriano G, Nicolai P, Licitra L, Machiels JP, Hamoir M, Andry G, Mehanna H, Hunter KD, Dietz A, René Leemans C. Simon C, et al. Among authors: thurnher d. Eur J Cancer. 2018 Nov;103:69-77. doi: 10.1016/j.ejca.2018.07.140. Epub 2018 Sep 11. Eur J Cancer. 2018. PMID: 30216847 Review.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
DRH1 - a novel blood-based HPV tumour marker.
Weiland T, Eckert A, Tomazic PV, Wolf A, Pondorfer P, Vasicek S, Graupp M, Holzmeister C, Moser U, Andrianakis A, Kangler G, Kiss P, Brcic L, Kappler M, Wickenhauser C, Haak A, Krüger M, Al-Nawas B, Blatt S, Brockmeyer N, Skaletz-Rorowski A, Potthoff A, French LE, Charnowski S, Reinholz M, Kaufmann AM, Thies S, Lambrecht HG, Seliger B, Wild DC, Thurnher D. Weiland T, et al. Among authors: thurnher d. EBioMedicine. 2020 Jun;56:102804. doi: 10.1016/j.ebiom.2020.102804. Epub 2020 Jun 11. EBioMedicine. 2020. PMID: 32535546 Free PMC article.
Neoplastic stem cells: a novel therapeutic target in clinical oncology.
Schulenburg A, Ulrich-Pur H, Thurnher D, Erovic B, Florian S, Sperr WR, Kalhs P, Marian B, Wrba F, Zielinski CC, Valent P. Schulenburg A, et al. Among authors: thurnher d. Cancer. 2006 Nov 15;107(10):2512-20. doi: 10.1002/cncr.22277. Cancer. 2006. PMID: 17039500 Free article. Review.
87 results